Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/pi3-kinase-inhibitors-in-chronic-lymphocytic-leukemia-1hmMTc73gZ
References (76)
-
D. Catovsky, S. Richards, E. Matutes, D. Oscier, M. Dyer, Rf Bezares, A. Pettitt, T. Hamblin, D. Milligan, J. Child, Hamilton, C. Dearden, Alastair Smith, A. Bosanquet, Z. Davis, V. Brito‐Babapulle, M. Else, R. Wade, P. Hillmen (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialThe Lancet, 370
-
IW Flinn, SM Horwitz, M Patel, A Younes, JR Porter, J Sweeney (2012)
Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, in Patients with Advanced Hematologic MalignanciesASH Annual Meeting Abstracts, 120
-
J. Sharman, S. Vos, J. Leonard, R. Furman, S. Coutre, I. Flinn, M. Schreeder, J. Barrientos, N. Wagner-Johnston, T. Boyd, N. Fowler, L. Holes, B. Lannutti, David Johnson, T. Jahn, L. Miller (2011)
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Blood, 118
-
HK Webb, H Chen, AS Yu, S Peterman, L Holes, B Lannutti (2010)
Clinical Pharmacokinetics of CAL-101, a p110{delta} Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological MalignanciesASH Annual Meeting Abstracts, 116
-
I. Flinn, E. Kimby, F. Cotter, F. Giles, A. Janssens, E. Pulczynski, Loic Ysebeart, A. Pluta, J. Marco, K. Taylor, C. Owen, D. Johnson, Maria Aiello, R. Dansey, R. Dubowy, Jeffrey Jones (2013)
A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).Journal of Clinical Oncology, 31
-
BS Kahl, NL Bartlett, JP Leonard, L Chen, K Ganjoo, ME Williams (2010)
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter studyCancer, 116
-
I Flinn, E Kimby, FE Cotter, FJ Giles, A Janssens, EJ Pulczynski (2013)
A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL)ASCO Meeting Abstracts, 31
-
K Ali, M Camps, WP Pearce, H Ji, T Ruckle, N Kuehn (2008)
Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivoJ Immunol, 180
-
BS Kahl, RR Furman, IW Flinn, JR Brown, ND Wagner-Johnston, SE Coutre (2013)
Final report of a phase I study of idelalisib, a selective inhibitor of PI3K-delta, in patients wtih relapsed or refractory indolent non-Hodgkin lymphoma (Poster presentation: 12th International Conference on Malignant Lymphoma, Lugano, Switzerland)Hematological Oncology, 31
-
N. Fowler, S. Vos, M. Schreeder, J. Leonard, I. Flinn, S. Coutre, N. Wagner-Johnston, J. Sharman, R. Boccia, J. Barrientos, T. Boyd, L. Holes, B. Lannutti, David Johnson, T. Jahn, L. Miller, W. Godfrey (2012)
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I StudyBlood, 120
-
K. Ali, M. Camps, W. Pearce, H. Ji, T. Rückle, N. Kuehn, C. Pasquali, C. Chabert, C. Rommel, B. Vanhaesebroeck (2008)
Isoform-Specific Functions of Phosphoinositide 3-Kinases: p110δ but Not p110γ Promotes Optimal Allergic Responses In Vivo1The Journal of Immunology, 180
-
J Leonard, ND Wagner-Johnston, SE Coutre, I Flinn, MT Schreeder, NH Fowler (2013)
Tolerability and activity of combinations of the PI3K{delta} inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I studyASCO Meeting Abstracts, 31
-
IW Flinn, MT Schreeder, N Wagner-Johnston, RV Boccia, JP Leonard, SE Coutre (2010)
A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell MalignanciesASH Annual Meeting Abstracts, 116
-
S. O'brien, N. Lamanna, T. Kipps, I. Flinn, A. Zelenetz, J. Burger, L. Holes, D. Johnson, J. Gu, R. Dansey, R. Dubowy, S. Coutre (2013)
A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).Journal of Clinical Oncology, 31
-
B. Cheson (2010)
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 21
-
M. Hallek, B. Cheson, D. Catovsky, F. Caligaris‐cappio, G. Dighiero, H. Döhner, P. Hillmen, M. Keating, E. Montserrat, K. Rai, T. Kipps (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.Blood, 111 12
-
Alexandra Smith, D. Howell, R. Patmore, A. Jack, A. Jack, E. Roman, E. Roman (2011)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research NetworkBritish Journal of Cancer, 105
-
B Kahl, JC Byrd, IW Flinn, N Wagner-Johnston, S Spurgeon, DM Benson (2010)
Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, In Patients with Relapsed or Refractory Non-Hodgkin LymphomaASH Annual Meeting Abstracts, 116
-
RR Furman, JC Barrientos, JP Sharman, S Vos, J Leonard, SE Coutre (2012)
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)ASCO Meeting Abstracts, 30
-
N. Schmitz, S. Zeynalova, B. Glass, U. Kaiser, E. Cavallin-ståhl, M. Wolf, M. Haenel, M. Loeffler, L. Trumper, M. Pfreundschuh (2010)
CNS Disease In Younger Patients (Blood, 116
-
B. Kahl, N. Bartlett, J. Leonard, Ling Chen, K. Ganjoo, Michael Williams, M. Czuczman, K. Robinson, R. Joyce, R. Jagt, B. Cheson (2009)
Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphomaCancer, 116
-
Jennifer Brown, R. Furman, I. Flinn, S. Coutre, N. Wagner-Johnston, B. Kahl, S. Spurgeon, D. Benson, S. Peterman, D. Johnson, Daniel Li, R. Dansey, T. Jahn, J. Byrd (2013)
Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.Journal of Clinical Oncology, 31
-
JR Brown, RR Furman, I Flinn, SE Coutre, ND Wagner-Johnston, BS Kahl (2013)
Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory CLLASCO Meeting Abstracts, 31
-
K. Fischer, P. Cramer, R. Busch, S. Stilgenbauer, J. Bahlo, C. Schweighofer, S. Böttcher, P. Staib, M. Kiehl, M. Eckart, G. Kranz, V. Goede, T. Elter, A. Bühler, D. Winkler, M. Kneba, H. Döhner, B. Eichhorst, M. Hallek, C. Wendtner (2011)
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 26
-
B. Cheson, J. Byrd, K. Rai, N. Kay, S. O'brien, I. Flinn, A. Wiestner, T. Kipps (2012)
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 23
-
J. Byrd, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, B. Grant, J. Sharman, M. Coleman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, J. Sukbuntherng, B. Chang, F. Clow, E. Hedrick, J. Buggy, D. James, S. O'brien (2013)
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.The New England journal of medicine, 369 1
-
K. Fischer, P. Cramer, S. Stilgenbauer, R. Busch, L. Balleisen, Julia Kilp, A. Fink, S. Boettcher, M. Ritgen, M. Kneba, P. Staib, H. Döhner, S. Schulte, B. Eichhorst, M. Hallek, C. Wendtner (2009)
Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).Blood, 114
-
J. Barrientos, R. Furman, J. Leonard, I. Flinn, K. Rai, S. Vos, M. Schreeder, N. Wagner-Johnston, J. Sharman, T. Boyd, N. Fowler, L. Holes, D. Johnson, Daniel Li, R. Dansey, T. Jahn, S. Coutre (2013)
Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.Journal of Clinical Oncology, 31
-
S. Coutre, J. Leonard, R. Furman, J. Barrientos, S. Vos, I. Flinn, M. Schreeder, N. Wagner-Johnston, J. Sharman, T. Boyd, N. Fowler, L. Holes, B. Lannutti, D. Johnson, L. Miller, T. Jahn (2012)
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I StudyBlood, 120
-
K Fischer, P Cramer, S Stilgenbauer, R Busch, L Balleisen, J Kilp (2009)
Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG)ASH Annual Meeting Abstracts, 114
-
R. Furman, J. Barrientos, J. Sharman, S. Vos, J. Leonard, S. Coutre, M. Schreeder, N. Wagner-Johnston, T. Boyd, N. Fowler, I. Flinn, R. Boccia, L. Holes, B. Lannutti, D. Johnson, T. Jahn, L. Miller (2012)
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).Journal of Clinical Oncology, 30
-
H. Webb, Hao Chen, A. Yu, S. Peterman, L. Holes, B. Lannutti, L. Miller, R. Ulrich (2010)
Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological MalignanciesBlood, 116
-
M. Hallek, K. Fischer, G. Fingerle-Rowson, A. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. Grünhagen, Matthias Bergmann, J. Catalano, P. Zinzani, F. Caligaris‐cappio, J. Seymour, A. Berrebi, U. Jäger, B. Cazin, M. Trněný, A. Westermann, C. Wendtner, B. Eichhorst, P. Staib, A. Bühler, D. Winkler, T. Zenz, S. Böttcher, M. Ritgen, M. Mendila, M. Kneba, H. Döhner, S. Stilgenbauer (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 376
-
J. Friedberg, J. Sharman, J. Sweetenham, P. Johnston, J. Vose, A. LaCasce, Julia Schaefer-Cutillo, S. Vos, R. Sinha, J. Leonard, L. Cripe, S. Gregory, Michael Sterba, A. Lowe, R. Levy, M. Shipp (2010)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.Blood, 115 13
-
DM Benson, BS Kahl, RR Furman, JR Brown, ND Wagner-Johnston, SE Coutre (2013)
Final results of a phase I study of idelalisib, a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)ASCO Meeting Abstracts, 31
-
D. Cantrell (2001)
Phosphoinositide 3-kinase signalling pathways.Journal of cell science, 114 Pt 8
-
M. Grever, D. Lucas, G. Dewald, D. Neuberg, John Reed, S. Kitada, I. Flinn, M. Tallman, F. Appelbaum, R. Larson, E. Paietta, D. Jelinek, J. Gribben, J. Byrd (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 7
-
N. Jain, S. O'brien (2012)
Chronic lymphocytic leukemia with deletion 17p: emerging treatment options.Oncology, 26 11
-
B. Coiffier, S. Leprêtre, L. Pedersen, O. Gadeberg, Henrik Fredriksen, M. Oers, J. Wooldridge, J. Kłoczko, J. Hołowiecki, A. Hellmann, J. Walewski, M. Flensburg, J. Petersen, T. Robak (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.Blood, 111 3
-
J. Perkins, J. Flynn, R. Howard, J. Byrd (2002)
Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphomaCancer, 94
-
IW Flinn, JR Brown, JC Byrd, SE Coutre, ND Wagner-Johnston, BS Kahl (2013)
Final report of a phase I study of idelalisib (GS-1101), a selective inhibitor of PI3K-delta, in patients with relapsed or refractory CLL (Poster presentation: 12th International Conference on Malignant Lymphoma, Lugano, Switzerland)Hematological Oncology, 31
-
SM O’Brien, N Lamanna, TJ Kipps, I Flinn, AD Zelenetz, JA Burger (2013)
A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K{delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) > =65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)ASCO Meeting Abstracts, 31
-
S. Stilgenbauer, T. Zenz, D. Winkler, A. Bühler, R. Schlenk, S. Groner, R. Busch, M. Hensel, U. Dührsen, J. Finke, P. Dreger, U. Jäger, E. Lengfelder, K. Hohloch, U. Söling, R. Schlag, M. Kneba, M. Hallek, H. Döhner (2009)
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 24
-
Ines Macias-Perez, I. Flinn (2013)
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic LeukemiaCurrent Hematologic Malignancy Reports, 8
-
I. Flinn, M. Schreeder, N. Wagner-Johnston, R. Boccia, J. Leonard, S. Coutre, L. Holes, S. Peterman, A. Yu (2010)
A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.Blood, 116
-
P. Hillmen, A. Skotnicki, T. Robak, B. Jakšić, A. Dmoszyńska, Jingyang Wu, C. Sirard, J. Mayer (2007)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 35
-
S Stilgenbauer, A Krober, R Busch, B Eichhorst, D Kienle, D Winkler (2005)
17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSGASH Annual Meeting Abstracts, 106
-
T. Bunney, M. Katan (2010)
Phosphoinositide signalling in cancer: beyond PI3K and PTENNature Reviews Cancer, 10
-
B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, B. Bilanges (2010)
The emerging mechanisms of isoform-specific PI3K signallingNature Reviews Molecular Cell Biology, 11
-
S. Horwitz, I. Flinn, M. Patel, A. Younes, F. Foss, Y. Oki, J. Sweeney, K. Allen, J. Dunbar, P. Kelly, B. Kahl (2013)
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma.Journal of Clinical Oncology, 31
-
JC Barrientos, RR Furman, J Leonard, I Flinn, KR Rai, S Vos (2013)
Update on a phase I study of the selective PI3K{delta} inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLLASCO Meeting Abstracts, 31
-
RR Furman, JC Byrd, JR Brown, SE Coutre, DM Benson, ND Wagner-Johnston (2010)
CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaASH Annual Meeting Abstracts, 116
-
IW Flinn, M Patel, S Horwitz, A Younes, FM Foss, Y Oki (2013)
Preliminary safety and efficacy of IPI-145: a potent inhibitor of phosphoinositide-3-kinase-delta-gamma, in patients wtih relapsed/refractory CLL/SLL (Oral presentation: 12th International Conference on Malignant Lymphoma, Lugano, Switzerland)Hematological Oncology, 31
-
T. Dennie, J. Kolesar (2009)
Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.Clinical therapeutics, 31 Pt 2
-
B. Vanhaesebroeck, M. Welham, Kei Kotani, R. Stein, P. Warne, M. Zvelebil, K. Higashi, S. Volinia, J. Downward, M. Waterfield (1997)
p110δ, a novel phosphoinositide 3-kinase in leukocytesProceedings of the National Academy of Sciences of the United States of America, 94
-
D. Benson, B. Kahl, R. Furman, Jennifer Brown, N. Wagner-Johnston, S. Coutre, S. Spurgeon, J. Byrd, J. Leonard, S. Peterman, D. Johnson, Yoonjin Cho, R. Dansey, W. Godfrey, I. Flinn (2013)
Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).Journal of Clinical Oncology, 31
-
J. Leonard, N. Wagner-Johnston, S. Coutre, I. Flinn, M. Schreeder, N. Fowler, J. Sharman, R. Boccia, J. Barrientos, K. Rai, T. Boyd, R. Furman, L. Holes, D. Johnson, Yeonhee Kim, R. Dansey, W. Godfrey, S. Vos (2013)
Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study.Journal of Clinical Oncology, 31
-
M. Choi, T. Kipps (2012)
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.Cancer journal, 18 5
-
I. Flinn, S. Horwitz, M. Patel, A. Younes, J. Porter, J. Sweeney, K. Allen, P. Kelly, B. Kahl (2012)
Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic MalignanciesBlood, 120
-
SE Coutre, JP Leonard, RR Furman, JC Barrientos, S Vos, IW Flinn (2012)
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I StudyASH Annual Meeting Abstracts, 120
-
W. Knauf, T. Lissichkov, A. Aldaoud, A. Liberati, J. Loscertales, R. Herbrecht, G. Juliusson, G. Postner, L. Gercheva, S. Goranov, M. Becker, H. Fricke, F. Huguet, I. Giudice, P. Klein, L. Tremmel, K. Merkle, M. Montillo (2009)
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
-
JG Perkins, JM Flynn, RS Howard, JC Byrd (2002)
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient populationCancer, 94
-
B Vanhaesebroeck, MJ Welham, K Kotani, R Stein, PH Warne, MJ Zvelebil (1997)
P110delta, a novel phosphoinositide 3-kinase in leukocytesProc Natl Acad Sci U S A, 94
-
RR Furman, SE Coutre, IW Flinn, JC Barrientos, K Rai, S Vos (2013)
Update on a phase I study of the selective PI3K-delta inhibitor idelalisib (GS-1101) in combination with rituximab, bendamustine, or bendamustine/rituximab in patients wtih relapsed or refractory chronic lymphocytic leukaemia (Poster presentation: 12th International Conference on Malignant Lymphoma, Lugano, Switzerland)Hematological Oncology, 31
-
J Sharman, S Vos, JP Leonard, RR Furman, SE Coutre, IW Flinn (2011)
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)ASH Annual Meeting Abstracts, 118
-
M. Keating, S. O'brien, D. Kontoyiannis, W. Plunkett, C. Koller, M. Beran, S. Lerner, H. Kantarjian (2002)
Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 43
-
B. Cheson, B. Pfistner, M. Juweid, R. Gascoyne, L. Specht, S. Horning, B. Coiffier, R. Fisher, A. Hagenbeek, E. Zucca, S. Rosen, S. Stroobants, T. Lister, R. Hoppe, M. Dreyling, K. Tobinai, J. Vose, J. Connors, M. Federico, V. Diehl (2007)
Revised response criteria for malignant lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 5
-
K. Okkenhaug (2013)
Signaling by the phosphoinositide 3-kinase family in immune cells.Annual review of immunology, 31
-
Michael Schmid, C. Avraamides, Holly Dippold, I. Franco, P. Foubert, L. Ellies, L. Acevedo, Joan Manglicmot, Xiaodan Song, W. Wrasidlo, S. Blair, M. Ginsberg, D. Cheresh, E. Hirsch, S. Field, J. Varner (2011)
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.Cancer cell, 19 6
-
S. Stilgenbauer, A. Kröber, R. Busch, B. Eichhorst, D. Kienle, D. Winkler, G. Hopfinger, P. Lichter, B. Emmerich, M. Hallek, H. Döhner (2005)
17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG.Blood, 106
-
C. Tam, S. O'brien, W. Wierda, H. Kantarjian, S. Wen, K. Do, D. Thomas, J. Cortes, S. Lerner, M. Keating (2008)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.Blood, 112 4
-
MR Patel, BS Kahl, SM Horwitz, A Younes, FM Foss, Y Oki (2013)
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed/refractory CLLASCO Meeting Abstracts, 31
-
I. Flinn, J. Byrd, R. Furman, Jennifer Brown, D. Benson, S. Coutre, B. Kahl, B. Smith, N. Wagner-Johnston, S. Spurgeon, N. Giese, A. Yu (2009)
Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.Blood, 114
-
B. Kahl, J. Byrd, I. Flinn, N. Wagner-Johnston, S. Spurgeon, D. Benson, R. Furman, Jennifer Brown, S. Coutre, B. Lannutti, N. Giese, R. Ulrich, H. Webb, S. Peterman, L. Holes, A. Yu (2010)
Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin LymphomaBlood, 116
-
NH Fowler, S Vos, MT Schreeder, JP Leonard, IW Flinn, S Coutre (2012)
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I StudyASH Annual Meeting Abstracts, 120
-
IW Flinn, JC Byrd, RR Furman, JR Brown, DM Benson, SE Coutre (2009)
Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110{Delta} Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell MalignanciesASH Annual Meeting Abstracts, 114
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0189-7
- pmid
- 24390602
- Publisher site
- See Article on Publisher Site
Abstract
The phosphatidylinositol 3-kinase (PI3K) pathway is being explored as a target of inhibition for B-cell lymphoproliferative disorders, with agents specific for inhibition of the PI3K-δ subunit showing significant clinical activity in chronic lymphocytic leukemia (CLL). Idelalisib (CAL-101, GS-1101) and IPI-145 (INK-1147) are novel oral PI3K-δ inhibitors in development, with rates of objective response of 40-60 % and nodal responses exceeding 70 % in relapsed and refractory CLL. High rates of response have been seen in high-risk CLL (i.e., 17p and 11q deletions), and may allow for more effective therapy in inherently chemotherapy-resistant disease. Combination chemotherapy regimens with idelalisib have similarly demonstrated favorable tolerability and activity. Like other agents that target the B-cell receptor pathway, peripheral lymphocytosis, due to drug-induced changes in lymphocyte trafficking, is common. Noteworthy toxicities include transaminitis and pneumonia/pneumonitis. Multiple studies are evaluating PI3K-δ inhibitor combination regimens, and the rationale for these ongoing and planned studies is reviewed.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Jan 7, 2014